NCT04503564View on ClinicalTrials.gov

"FEXIS: (Feasibility of an Extended Wear CSII Set in Participants With T1DM)"

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 13, 2019

Primary Completion Date

November 11, 2020

Study Completion Date

November 11, 2020

Conditions
Diabetes Mellitus, Type 1Type 1 DiabetesType 1 Diabetes MellitusDiabetes Mellitus, Insulin-Dependent, 1
Interventions
DEVICE

coil-reinforced soft polymer indwelling cannula

This is a prospective, non-randomized, home-use feasibility study of device performance, usability, tolerability, and safety of the Capillary Biomedical, Inc. (CapBio) Achilles infusion set for continuous subcutaneous insulin infusion (CSII or insulin pump therapy) in up to 20 participants diagnosed with type 1 diabetes mellitus (T1DM).

Trial Locations (1)

Unknown

St Vincent's Hospital (Melbourne) Ltd - Fitzroy, Melbourne

Sponsors
All Listed Sponsors
lead

Capillary Biomedical, Inc.

INDUSTRY

NCT04503564 - "FEXIS: (Feasibility of an Extended Wear CSII Set in Participants With T1DM)" | Biotech Hunter | Biotech Hunter